About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
CEO and Founder: Jan G. J. van de Winkel, Ph.D.
CFO: David Eatwell
JOBS: Please click here for Genmab job opportunities.
Please click here for clinical trial information.
FOLLOW GENMAB: Tweets by Genmab
357 articles with Genmab A/S
Genmab Announces Novartis’ Intention to Transition Arzerra (ofatumumab) From Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-U.S. Markets
As a consequence, Novartis will pay Genmab a lump sum of USD 50 million as payment for lost potential milestones and royalties.
As of January 5, 2018, Artisan Partners Limited Partnership has increased their indirect ownership in Genmab A/S to 3,081,731 shares.
A look at whether big money and big deals will be in store for 2018.
Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab
Genmab announced today that at a board meeting the board decided to grant 49,680 restricted stock units to members of the board of directors, management and employees of the company as well as the company's subsidiaries and 139,597 warrants to management and employees of the company as well as the company's subsidiaries.
Genmab speakers will also discuss the company’s 2017 progress and key goals for 2018.
The meeting will include updates on daratumumab, including presentations by key opinion leaders on data from daratumumab studies presented at the 59th Annual Meeting of the American Society of Hematology (ASH).
Genmab just received a $20M milestone payment from Janssen Biotech.
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.
Data from Phase III ALCYONE Study of Daratumumab Accepted for Oral Presentation at Annual Meeting of the American Society of Hematology
The abstract is published online on the ASH website: www.hematology.org.
The milestone was triggered by confirmation by Janssen that sales of Darzalex reached $1 billion in a calendar year.
Genmab Achieves $25M Milestone for First Commercial Sale of DARZALEX® (daratumumab) in Japan and Updates Financial Guidance
First commercial sale of DARZALEX in Japan triggers USD 25 million in milestone payments from Janssen.
The company will increase its share capital by 22,532 shares as a consequence of the exercise of employee warrants.
BlackRock has increased their indirect ownership in Genmab to 3,076,324 shares, which amounts to 5.03% of the share capital and voting rights in Genmab.
Shareholders must submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors no later than Monday, February 26, 2018.
Genmab Announces Additional Information Concerning Net Sales of DARZALEX (daratumumab) for Third Quarter of 2017
Net sales of DARZALEX in the third quarter of 2017 totaled USD 317 million.
Genmab A/S And Seattle Genetics To Initiate New Study Of Novel Antibody-Drug Conjugate Tisotumab Vedotin In Cervical Cancer
Genmab A/S Announces Approval Of DARZALEX (Daratumumab) For Relapsed Or Refractory Multiple Myeloma In Japan